Equities

Tenaya Therapeutics Inc

TNYA:NSQ

Tenaya Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.19
  • Today's Change0.17 / 8.42%
  • Shares traded312.39k
  • 1 Year change-20.07%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments105187251
Total Receivables, Net------
Total Inventory------
Prepaid expenses5.787.234.06
Other current assets, total1.16----
Total current assets112194255
Property, plant & equipment, net536355
Goodwill, net------
Intangibles, net------
Long term investments018--
Note receivable - long term------
Other long term assets5.684.793.58
Total assets171279314
LIABILITIES
Accounts payable5.639.5811
Accrued expenses171511
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.49--0.16
Total current liabilities232422
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total8.361114
Total liabilities313636
SHAREHOLDERS EQUITY
Common stock0.010.010.00
Additional paid-in capital543523434
Retained earnings (accumulated deficit)(403)(279)(156)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.11)(0.38)(0.14)
Total equity139243279
Total liabilities & shareholders' equity171279314
Total common shares outstanding686741
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.